key: cord-0720485-iy3fkrby
authors: Miyazawa, Daisuke; Kaneko, Gen
title: Clinical trials of inhaled beclomethasone and mometasone for COVID‐19 should be conducted
date: 2020-08-16
journal: J Med Virol
DOI: 10.1002/jmv.26413
sha: f83f50ab75c9a9e4b2a8de94b8ddaee910b0c25b
doc_id: 720485
cord_uid: iy3fkrby

Several recent studies have reported that systemic corticosteroids are effective against COVID-191 . COVID-19 mainly affects the respiratory system, with minor damage to other organs. This article is protected by copyright. All rights reserved.

Nebulized budesonide improved oxygenation and significantly reduced inflammatory markers (tumor necrosis factor-α, interleukin 1β [IL-1β], and IL-6) in patients with acute respiratory distress syndrome. 5 There are several reviews of inhaled corticosteroids for COVID-19, but there is no clear evidence on whether the premorbid use of ICS has adverse or beneficial outcomes in COVID-19 patients. 6, 7 ICS can reach different sites in the lungs, depending on their particle sizes. 8 As the alveoli are the main sites for lung inflammation in COVID-19, steroids with smaller particle sizes that can efficiently reach the alveoli could be more promising. Among ICS, beclomethasone and ciclesonide, administered through pressurized metered-dose inhalers (pMDIs) have the smallest particle sizes (<2 µm) and reach the alveoli more easily. 8 The particles in the nebulizer are also small enough to reach the alveoli, but there is a concern that the exhaled particles may contain the virus, and could, therefore, infect medical personnel.

Apart from their anti-inflammatory effects, some ICS have been found to have antiviral effects. ICS, namely ciclesonide and mometasone suppressed the replication of SARS-CoV-2 and MERS-CoV in vitro, whereas dexamethasone, cortisone, prednisolone, and fluticasone did not exert antiviral effects. 9 A recent case report showed favorable outcomes in three COVID-19 patients treated with inhaled ciclesonide. 10 Compared to ICS administered through pMDIs, it is more difficult for corticosteroids administered through dry powder inhalers (DPI) to reach the alveoli, owing to their larger particle sizes.

Mometasone may be worth considering, as it has antiviral properties and smaller particle size than budesonide. 6 Moreover, a mutant strain of ciclesonide-resistant MERS-CoV did not show resistance to mometasone. 7 As of 5 July 2020, several clinical trials worldwide utilizing ICS for COVID-19 have been registered on ClinicalTrials.gov: four trials (one recruiting, three not yet) for ciclesonide and four trials (three recruiting, one not yet) for budesonide (one including formoterol).

The antiviral effects of inhaled corticosteroids as well as their smaller particle sizes, which is related to their ability to efficiently reach the alveoli, should be noted. Previous studies have not reported the anti-SARS-COV-2 effects of beclomethasone in vitro. We propose that clinical trials that test the clinical effects of beclomethasone, which has a similar particle size to ciclesonide, as well as studies that confirm its antiviral effects, should be conducted. This is because, if either or both drugs are found to be effective, it may be possible to speculate whether these effects are due to their antiviral or their anti-inflammatory effects. If beclomethasone is found to be clinically effective but not antiviral, the effect of particle size can be estimated by comparing it to budesonide, which also has no antiviral effect. For the same reason and in anticipation of the unique antiviral effect that is different from ciclesonide, we propose that clinical trials of mometasone, which have a smaller but similar particle size to budesonide, should also be conducted. Mometasone is also available in the form of a nasal spray, and clinical trials could be conducted to determine the preventive effects of intranasal mometasone in treating early-stage COVID-19.

The DPI requires a certain respiratory rate for inhalation, as the powder is inhaled by the patient. In contrast, the pMDIs use pressurized gas to atomize the drug and eject it into the air, making it suitable for use by compromised patients with a low respiratory rate.

Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv

Acute respiratory failure in COVID-19: is it "typical

SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response

Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis

Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/acute respiratory distress syndrome: randomized controlled study

COVID-19, asthma, and inhaled corticosteroids: another beneficial effect of inhaled corticosteroids?

Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective

From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled corticosteroids

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: report of three cases